Share This:
https://ntp.niehs.nih.gov/go/9112

TDMS Study 92012-05 Pathology Tables

NTP Experiment-Test: 92012-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                         2-METHYLIMIDAZOLE                                     Date: 02/24/03
Route: DOSED FEED                                                                                                 Time: 14:26:13

                                                         FINAL #1/RATS




       Facility:  Southern Research Institute

       Chemical CAS #:  693-98-1

       Lock Date:  10/16/01

       Cage Range:  All

       Reasons For Removal:    25019 Moribund Sacrifice                25020 Natural Death
                               25021 Terminal Sacrifice

       Removal Date Range:     All

       Treatment Groups:       Include All

































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 92012-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                         2-METHYLIMIDAZOLE                                     Date: 02/24/03  
Route: DOSED FEED                                                                                                 Time: 14:26:13  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS FEMALE                   0PPM         1000 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          60           60           60           60                                     
  Early Deaths                                                                                                                      
    Natural Death                                      4            3           10            1                                     
    Moribund Sacrifice                                 6            8           12            7                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                40           39           28           41                                     
    Natural Death                                                                             1                                     
                                                                                                                                    
  Animals Examined Microscopically                    50           50           50           50                                     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Large, Colon                             (48)         (49)         (48)         (50)                                   
   Intestine Large, Rectum                            (47)         (48)         (50)         (49)                                   
   Intestine Large, Cecum                             (48)         (47)         (44)         (50)                                   
   Intestine Small, Duodenum                          (48)         (49)         (49)         (50)                                   
   Intestine Small, Jejunum                           (47)         (46)         (44)         (49)                                   
   Intestine Small, Ileum                             (48)         (46)         (44)         (50)                                   
   Liver                                              (50)         (49)         (50)         (50)                                   
      Cholangiocarcinoma                               1 (2%)                                 1 (2%)                                
      Hepatocellular Adenoma                           1 (2%)                    2 (4%)       3 (6%)                                
      Hepatocellular Adenoma, Multiple                                                        1 (2%)                                
   Mesentery                                          (8)          (10)         (12)         (9)                                    
      Nerve, Schwannoma Malignant                                                             1 (11%)                               
   Pancreas                                           (50)         (49)         (49)         (50)                                   
   Salivary Glands                                    (50)         (49)         (50)         (50)                                   
   Stomach, Forestomach                               (50)         (50)         (50)         (50)                                   
      Squamous Cell Papilloma                                                    1 (2%)                                             
   Stomach, Glandular                                 (49)         (49)         (48)         (50)                                   
   Tongue                                             (3)                       (1)                                                 
      Liposarcoma                                      1 (33%)                                                                      
      Squamous Cell Papilloma                                                    1 (100%)                                           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (50)         (49)         (50)         (50)                                   
      Squamous Cell Carcinoma, Metastatic, Skin                                  1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 92012-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                         2-METHYLIMIDAZOLE                                     Date: 02/24/03  
Route: DOSED FEED                                                                                                 Time: 14:26:13  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS FEMALE                   0PPM         1000 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (50)         (49)         (50)         (50)                                   
      Adenoma                                          5 (10%)                                                                      
   Adrenal Medulla                                    (49)         (49)         (50)         (50)                                   
      Pheochromocytoma Malignant                                                 1 (2%)                                             
      Pheochromocytoma Benign                                       2 (4%)                                                          
   Islets, Pancreatic                                 (50)         (49)         (50)         (50)                                   
      Adenoma                                                                    1 (2%)       1 (2%)                                
      Carcinoma                                        2 (4%)                                                                       
   Pituitary Gland                                    (50)         (48)         (50)         (50)                                   
      Pars Distalis, Adenoma                          23 (46%)     24 (50%)     21 (42%)     13 (26%)                               
      Pars Distalis, Carcinoma                         2 (4%)       1 (2%)       3 (6%)                                             
      Pars Intermedia, Adenoma                                      1 (2%)                                                          
   Thyroid Gland                                      (49)         (48)         (42)         (48)                                   
      Bilateral, C-Cell, Adenoma                       1 (2%)                                                                       
      Bilateral, C-Cell, Adenoma, Multiple             1 (2%)                                                                       
      Bilateral, Follicular Cell, Adenoma                                                     1 (2%)                                
      Bilateral, Follicular Cell, Carcinoma                                                   1 (2%)                                
      C-Cell, Adenoma                                  7 (14%)      8 (17%)      8 (19%)      3 (6%)                                
      C-Cell, Adenoma, Multiple                                     1 (2%)                                                          
      C-Cell, Carcinoma                                             1 (2%)                    1 (2%)                                
      Follicular Cell, Adenoma                                                                4 (8%)                                
      Follicular Cell, Carcinoma                       1 (2%)       1 (2%)       1 (2%)       6 (13%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   Tissue NOS                                         (3)                       (4)          (2)                                    
      Mediastinum, Squamous Cell Carcinoma,                                                                                         
          Metastatic, Skin                                                       1 (25%)                                            
      Thoracic, Fibrosarcoma                           1 (33%)                                                                      
      Thoracic, Rhabdomyosarcoma                                                 1 (25%)                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Clitoral Gland                                     (50)         (49)         (50)         (50)                                   
      Adenoma                                          5 (10%)      4 (8%)       5 (10%)                                            
      Carcinoma                                        3 (6%)       1 (2%)       1 (2%)       1 (2%)                                
      Squamous Cell Papilloma                          1 (2%)                                                                       
      Bilateral, Adenoma                                                         1 (2%)                                             
      Bilateral, Carcinoma, Multiple                                1 (2%)                                                          
   Ovary                                              (50)         (49)         (50)         (50)                                   
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 92012-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                         2-METHYLIMIDAZOLE                                     Date: 02/24/03  
Route: DOSED FEED                                                                                                 Time: 14:26:13  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS FEMALE                   0PPM         1000 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
GENITAL SYSTEM - cont                                                                                                               
      Granulosa Cell Tumor Benign                                                             1 (2%)                                
      Granulosa-Theca Tumor Benign                                               1 (2%)                                             
   Uterus                                             (50)         (50)         (50)         (50)                                   
      Endometrium, Polyp Stromal                       7 (14%)      6 (12%)      7 (14%)      3 (6%)                                
      Endometrium, Polyp Stromal, Multiple             1 (2%)                                                                       
   Vagina                                             (2)                       (2)                                                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (49)         (50)         (50)         (50)                                   
   Lymph Node                                         (32)         (31)         (34)         (41)                                   
   Lymph Node, Mesenteric                             (49)         (49)         (49)         (50)                                   
   Spleen                                             (50)         (49)         (48)         (50)                                   
   Thymus                                             (48)         (45)         (49)         (49)                                   
      Thymoma Malignant                                                          1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (50)         (50)         (50)         (50)                                   
      Carcinoma                                        4 (8%)       1 (2%)       3 (6%)       1 (2%)                                
      Fibroadenoma                                    24 (48%)     18 (36%)     18 (36%)      5 (10%)                               
      Fibroadenoma, Multiple                           2 (4%)       5 (10%)      6 (12%)      1 (2%)                                
   Skin                                               (50)         (50)         (50)         (50)                                   
      Basal Cell Adenoma                               1 (2%)                                                                       
      Basal Cell Carcinoma                             1 (2%)                                                                       
      Keratoacanthoma                                                                         1 (2%)                                
      Squamous Cell Carcinoma, Multiple                                          1 (2%)                                             
      Subcutaneous Tissue, Fibroma                     1 (2%)                    2 (4%)       2 (4%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Skeletal Muscle                                    (1)          (1)          (2)                                                 
      Rhabdomyosarcoma                                              1 (100%)     1 (50%)                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 92012-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                         2-METHYLIMIDAZOLE                                     Date: 02/24/03  
Route: DOSED FEED                                                                                                 Time: 14:26:13  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS FEMALE                   0PPM         1000 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (50)         (49)         (50)         (50)                                   
      Glioma Malignant, Mixed Cell                                                            1 (2%)                                
   Spinal Cord                                        (3)          (1)          (4)                                                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)         (49)         (50)         (50)                                   
      Alveolar/Bronchiolar Adenoma                                  1 (2%)       1 (2%)       1 (2%)                                
      Rhabdomyosarcoma, Metastatic, Tissue NOS                                   1 (2%)                                             
      Squamous Cell Carcinoma, Metastatic, Skin                                  1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Eye                                                (50)         (49)         (49)         (50)                                   
   Harderian Gland                                    (50)         (49)         (50)         (50)                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (50)         (48)         (47)         (50)                                   
      Sarcoma                                                                                 1 (2%)                                
      Squamous Cell Carcinoma, Metastatic, Skin                                  1 (2%)                                             
   Urinary Bladder                                    (50)         (49)         (49)         (50)                                   
      Transitional Epithelium, Papilloma               1 (2%)       1 (2%)                                                          
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(50)        *(50)        *(50)        *(50)                                   
      Leukemia Mononuclear                             6 (12%)      4 (8%)       9 (18%)     10 (20%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 92012-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                         2-METHYLIMIDAZOLE                                     Date: 02/24/03  
Route: DOSED FEED                                                                                                 Time: 14:26:13  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS FEMALE                   0PPM         1000 PPM     2500 PPM     5000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            45          44          48          38                                       
     Total Primary Neoplasms                          103          82          97          64                                       
                                                                                                                                    
   Total Animals with Benign Neoplasms                 43          43          40          27                                       
     Total Benign Neoplasms                            81          71          75          40                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms              19          10          21          20                                       
     Total Malignant Neoplasms                         22          11          22          24                                       
                                                                                                                                    
   Total Animals with Metastatic Neoplasms                                      2                                                   
     Total Metastatic Neoplasm                                                  5                                                   
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 92012-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                         2-METHYLIMIDAZOLE                                     Date: 02/24/03  
Route: DOSED FEED                                                                                                 Time: 14:26:13  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS MALE                     0PPM         300 PPM      1000 PPM     3000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          60           60           60           60                                     
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                13            6            7           13                                     
    Natural Death                                      2            4            7            2                                     
  Survivors                                                                                                                         
    Terminal Sacrifice                                34           39           35           35                                     
    Moribund Sacrifice                                 1                                                                            
    Natural Death                                                   1            1                                                  
                                                                                                                                    
  Animals Examined Microscopically                    50           50           50           50                                     
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Large, Colon                             (50)         (49)         (48)         (50)                                   
   Intestine Large, Rectum                            (49)         (48)         (48)         (50)                                   
   Intestine Large, Cecum                             (48)         (45)         (45)         (49)                                   
      Lipoma                                                                     1 (2%)                                             
   Intestine Small, Duodenum                          (49)         (49)         (48)         (50)                                   
   Intestine Small, Jejunum                           (47)         (45)         (44)         (48)                                   
      Leiomyosarcoma                                                             1 (2%)                                             
   Intestine Small, Ileum                             (47)         (46)         (45)         (48)                                   
   Liver                                              (50)         (50)         (50)         (50)                                   
      Cholangiocarcinoma                               1 (2%)       2 (4%)       2 (4%)       1 (2%)                                
      Cholangioma                                                   2 (4%)                                                          
      Hemangiosarcoma                                               1 (2%)                                                          
      Hepatocellular Carcinoma                                                   1 (2%)       2 (4%)                                
      Hepatocellular Adenoma                                        1 (2%)       3 (6%)       1 (2%)                                
      Hepatocellular Adenoma, Multiple                                                        1 (2%)                                
   Mesentery                                          (26)         (46)         (35)         (20)                                   
      Hemangiosarcoma                                  1 (4%)       1 (2%)                                                          
   Oral Mucosa                                                                  (1)                                                 
      Squamous Cell Papilloma                                                    1 (100%)                                           
   Pancreas                                           (49)         (49)         (50)         (50)                                   
      Acinus, Adenoma                                  1 (2%)                                                                       
   Salivary Glands                                    (50)         (50)         (50)         (50)                                   
   Stomach, Forestomach                               (50)         (50)         (50)         (49)                                   
   Stomach, Glandular                                 (50)         (50)         (50)         (49)                                   
      Adenoma                                                                                 1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 92012-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                         2-METHYLIMIDAZOLE                                     Date: 02/24/03  
Route: DOSED FEED                                                                                                 Time: 14:26:13  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS MALE                     0PPM         300 PPM      1000 PPM     3000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (50)         (50)         (50)         (50)                                   
      Pericardium, Epicardium,                                                                                                      
          Alveolar/Bronchiolar Carcinoma,                                                                                           
          Metastatic, Lung                                                       1 (2%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (50)         (50)         (50)         (50)                                   
      Adenoma                                                       1 (2%)                                                          
   Adrenal Medulla                                    (50)         (50)         (50)         (50)                                   
      Pheochromocytoma Malignant                                    1 (2%)       3 (6%)       1 (2%)                                
      Pheochromocytoma Benign                          7 (14%)      2 (4%)       6 (12%)      6 (12%)                               
      Schwannoma Malignant, Metastatic, Adrenal                                                                                     
          Medulla                                                                1 (2%)                                             
      Bilateral, Pheochromocytoma Benign               1 (2%)       1 (2%)                                                          
   Islets, Pancreatic                                 (50)         (49)         (50)         (50)                                   
      Adenoma                                                                    1 (2%)       3 (6%)                                
      Carcinoma                                                     3 (6%)                                                          
   Pituitary Gland                                    (50)         (50)         (50)         (50)                                   
      Pars Distalis, Adenoma                           9 (18%)      6 (12%)      8 (16%)      8 (16%)                               
      Pars Distalis, Adenoma, Multiple                                                        1 (2%)                                
      Pars Intermedia, Adenoma                         1 (2%)                                                                       
   Thyroid Gland                                      (48)         (46)         (43)         (50)                                   
      Bilateral, C-Cell, Adenoma                       1 (2%)                                                                       
      Bilateral, C-Cell, Adenoma, Multiple                                                    1 (2%)                                
      C-Cell, Adenoma                                  8 (17%)      5 (11%)      9 (21%)      6 (12%)                               
      C-Cell, Carcinoma                                1 (2%)                                 3 (6%)                                
      Follicular Cell, Adenoma                         1 (2%)                    1 (2%)       3 (6%)                                
      Follicular Cell, Carcinoma                                    2 (4%)                    2 (4%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   Peritoneum                                         (1)          (3)                                                              
   Tissue NOS                                         (7)          (2)          (6)          (4)                                    
      Sarcoma                                          1 (14%)                                                                      
      Mediastinum, Alveolar/Bronchiolar Carcinoma,                                                                                  
           Metastatic, Lung                                                      1 (17%)                                            
      Thoracic, Alveolar/Bronchiolar Carcinoma,                                                                                     
           Metastatic, Lung                                                      1 (17%)                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 92012-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                         2-METHYLIMIDAZOLE                                     Date: 02/24/03  
Route: DOSED FEED                                                                                                 Time: 14:26:13  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS MALE                     0PPM         300 PPM      1000 PPM     3000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Epididymis                                         (50)         (50)         (50)         (50)                                   
   Preputial Gland                                    (50)         (50)         (50)         (50)                                   
      Adenoma                                                       1 (2%)       2 (4%)                                             
      Adenoma, Cystic                                                            1 (2%)                                             
      Carcinoma                                                     1 (2%)       2 (4%)       3 (6%)                                
      Bilateral, Carcinoma                                          1 (2%)                                                          
   Prostate                                           (50)         (50)         (50)         (50)                                   
   Seminal Vesicle                                    (50)         (50)         (50)         (50)                                   
   Testes                                             (50)         (50)         (50)         (50)                                   
      Bilateral, Interstitial Cell, Adenoma            2 (4%)                                                                       
      Bilateral, Interstitial Cell, Adenoma,                                                                                        
          Multiple                                    42 (84%)     36 (72%)     34 (68%)     28 (56%)                               
      Interstitial Cell, Adenoma                       3 (6%)       2 (4%)       6 (12%)      7 (14%)                               
      Interstitial Cell, Adenoma, Multiple             1 (2%)       7 (14%)      2 (4%)       8 (16%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (50)         (50)         (47)         (50)                                   
   Lymph Node                                         (39)         (49)         (42)         (38)                                   
      Deep Cervical, Carcinoma, Metastatic,                                                                                         
          Zymbal's Gland                                            1 (2%)                                                          
   Lymph Node, Mesenteric                             (47)         (50)         (50)         (50)                                   
   Spleen                                             (49)         (49)         (50)         (50)                                   
   Thymus                                             (48)         (48)         (44)         (49)                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (48)         (47)         (45)         (42)                                   
      Fibroadenoma                                                                            2 (5%)                                
   Skin                                               (50)         (50)         (50)         (50)                                   
      Basal Cell Carcinoma                                                                    2 (4%)                                
      Keratoacanthoma                                  1 (2%)       2 (4%)       1 (2%)       4 (8%)                                
      Melanoma Benign                                                            1 (2%)                                             
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                         1 (2%)                                                                       
      Trichoepithelioma                                1 (2%)                    1 (2%)       1 (2%)                                
      Dermis, Fibroma                                               1 (2%)                                                          
      Pinna, Schwannoma Malignant                      1 (2%)                                                                       
      Sebaceous Gland, Adenoma                                                                1 (2%)                                
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
NTP Experiment-Test: 92012-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                         2-METHYLIMIDAZOLE                                     Date: 02/24/03  
Route: DOSED FEED                                                                                                 Time: 14:26:13  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS MALE                     0PPM         300 PPM      1000 PPM     3000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
INTEGUMENTARY SYSTEM - cont                                                                                                         
      Subcutaneous Tissue, Fibroma                     1 (2%)       3 (6%)                    2 (4%)                                
      Subcutaneous Tissue, Fibroma, Multiple           1 (2%)                                                                       
      Subcutaneous Tissue, Fibrosarcoma                                          1 (2%)       1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (50)         (50)         (50)         (50)                                   
      Osteosarcoma                                                                            1 (2%)                                
      Cranium, Carcinoma, Metastatic, Zymbal's                                                                                      
          Gland                                                     1 (2%)                                                          
      Cranium, Osteoma                                 2 (4%)                                                                       
      Cranium, Osteosarcoma                                                                   1 (2%)                                
   Skeletal Muscle                                    (2)          (1)          (1)          (4)                                    
      Hemangiosarcoma                                  1 (50%)                                                                      
      Rhabdomyosarcoma                                                                        1 (25%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   Brain                                              (50)         (50)         (50)         (50)                                   
      Astrocytoma Malignant                                                                   1 (2%)                                
   Spinal Cord                                        (1)                       (1)                                                 
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)         (50)         (50)         (50)                                   
      Alveolar/Bronchiolar Adenoma                     2 (4%)       2 (4%)       2 (4%)       1 (2%)                                
      Alveolar/Bronchiolar Carcinoma                   2 (4%)       1 (2%)       1 (2%)                                             
      Alveolar/Bronchiolar Carcinoma, Multiple                                   1 (2%)                                             
      Carcinoma, Metastatic, Preputial Gland                                                  1 (2%)                                
      Carcinoma, Metastatic, Zymbal's Gland                         1 (2%)                                                          
      Osteosarcoma, Metastatic, Bone                                                          1 (2%)                                
      Alveolar Epithelium, Carcinoma                                             1 (2%)                                             
   Nose                                               (50)         (50)         (50)         (50)                                   
      Glands, Adenoma                                  1 (2%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  10                                                               
                                                                                                                                   
NTP Experiment-Test: 92012-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                         2-METHYLIMIDAZOLE                                     Date: 02/24/03  
Route: DOSED FEED                                                                                                 Time: 14:26:13  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS MALE                     0PPM         300 PPM      1000 PPM     3000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                    (50)         (50)         (49)         (50)                                   
   Zymbal's Gland                                                  (1)          (2)                                                 
      Carcinoma                                                     1 (100%)     2 (100%)                                           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (49)         (49)         (49)         (50)                                   
   Urinary Bladder                                    (50)         (50)         (49)         (50)                                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(50)        *(50)        *(50)        *(50)                                   
      Leukemia Mononuclear                            15 (30%)     14 (28%)     21 (42%)     10 (20%)                               
      Lymphoma Malignant                                                                      1 (2%)                                
      Mesothelioma Malignant                           2 (4%)       4 (8%)       2 (4%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  11                                                               
                                                                                                                                   
NTP Experiment-Test: 92012-05  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                         2-METHYLIMIDAZOLE                                     Date: 02/24/03  
Route: DOSED FEED                                                                                                 Time: 14:26:13  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         FISCHER 344 RATS MALE                     0PPM         300 PPM      1000 PPM     3000 PPM                                  
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            50          49          49          48                                       
     Total Primary Neoplasms                          111         104         118         115                                       
                                                                                                                                    
   Total Animals with Benign Neoplasms                 49          46          47          45                                       
     Total Benign Neoplasms                            86          72          80          85                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms              22          26          30          25                                       
     Total Malignant Neoplasms                         25          32          38          30                                       
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              1           2           2           2                                       
     Total Metastatic Neoplasm                          1           4           4           2                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms               1                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  12                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------